Virtual Library
Start Your Search
J. Mazieres
Moderator of
-
+
Developments in pharmacology for systemic therapy (ID 11)
- Event: ELCC 2018
- Type: Specialty session
- Track:
- Presentations: 4
- Now Available
- Moderators:D. Carbone, J. Mazieres
- Coordinates: 4/12/2018, 11:00 - 12:30, Room A
-
+
Dosing and scheduling of monoclonal antibodies (ID 44)
11:20 - 11:40 | Presenting Author(s): T. Yap
- Abstract
Abstract not provided
-
+
Interactions of immunotherapy with other therapies (Now Available) (ID 46)
12:00 - 12:20 | Presenting Author(s): S. Champiat
- Abstract
- Presentation
Abstract not provided
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
-
+
Pharmacokinetics and interaction for TKI treatment (Now Available) (ID 43)
11:00 - 11:20 | Presenting Author(s): S. Popat
- Abstract
- Presentation
Abstract not provided
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
-
+
Target treatment combinations: Rationale and evidence (Now Available) (ID 45)
11:40 - 12:00 | Presenting Author(s): D. Carbone
- Abstract
- Presentation
Abstract not provided
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
Author of
-
+
Immunotherapy and next-generation TKIs: From second to frontline treatment (ID 55)
- Event: ELCC 2018
- Type: Poster Discussion session
- Track:
- Presentations: 1
- Moderators:P. Garrido Lopez, S. Ekman, S. Ortiz-Cuaran, E. Wauters
- Coordinates: 4/12/2018, 07:45 - 09:00, Room A
-
+
136PD_PR - 3-year survival and duration of response in randomized phase II study of atezolizumab (atezo) vs docetaxel (doc) in 2L+ NSCLC (POPLAR) (ID 607)
10:54 - 10:54 | Presenting Author(s): J. Mazieres
- Abstract
Background:
Atezo (anti–PD-L1) has demonstrated OS benefit over doc in a randomized Phase II study, POPLAR, in patients with advanced NSCLC. This benefit has been confirmed in the randomized Phase III study OAK (Rittmeyer, 2017). The 3-year survival analysis of the POPLAR study presented here describes the longest survival follow-up reported to date of an all-comer randomized PD-L1/PD-1 immunotherapy trial in 2L + NSCLC.
Methods:
Patients were randomized 1:1 to receive atezo (1200 mg) or doc (75 mg/m[2]) IV q3w. Tumors were prospectively evaluated for tumor cell (TC) or tumor-infiltrating immune cell (IC) PD-L1 expression using the VENTANA SP142 IHC assay. Landmark OS was estimated using the Kaplan-Meier method. Data cutoff, April 7, 2017; minimum follow-up, 3 years.
Results:
The 2-year and 3-year survival with atezo vs doc were 32.2% vs 16.6% and 18.7% vs 10.0%, respectively. The long-term OS benefit of atezo vs doc was observed across histology and PD-L1 expression subgroups (Table). While the TC3 or IC3 subgroup derived the greatest OS benefit, the TC0 and IC0 subgroup also had improved long-term OS with atezo vs doc. The ITT ORR was 15% in both atezo and doc arms, but the median duration of response was 3 times longer with atezo (22.3 months [95% CI: 11.6, 31.1] vs 7.2 months [95% CI: 5.8, 12.2] with doc). Seven of the 11 doc-arm 3-year survivors received subsequent non-protocol therapy with anti–PD-L1/PD-1 agents. Atezo had a favorable safety profile compared with doc that was consistent with previous reports.Table:Landmark OS in the ITT, PD-L1 expression, and histology subgroups in POPLAR
aFor descriptive purpose only. TC3 or IC3 = PD-L1 ≥ 50% TC or 10% IC; TC2/3 or IC2/3 = PD-L1 ≥ 5% TC or IC; TC1/2/3 or IC1/2/3 = PD-L1 ≥ 1% TC or IC; TC0 and IC0 = PD-L1 < 1% TC and IC. NCT01903993.Population (n, atezo vs doc) 2-year OS rate, % 3-year OS rate, % Atezo Doc P value[a] Atezo Doc P value[a] ITT (144 vs 143) 32.2% 16.6% 0.0027 18.7% 10.0% 0.0419 PD-L1 Expression Subgroups TC3 or IC3 (24 vs 23) 41.7% 19.9% 0.1003 37.5% 14.9% 0.0724 TC2/3 or IC2/3 (50 vs 55) 36.1% 13.8% 0.0082 21.2% 9.9% 0.1166 TC1/2/3 or IC1/2/3 (93 vs 102) 36.0% 19.8% 0.0124 18.0% 11.0% 0.1759 TC0 and IC0 (51 vs 41) 25.0% 6.8% 0.0202 20.5% 6.8% 0.0693 Histology Subgroups Non-squamous (95 vs 95) 32.2% 21.1% 0.0960 23.3% 12.4% 0.0585 Squamous (49 vs 48) 32.7% 7.8% 0.0020 9.4% 5.2% 0.4603
Conclusions:
Atezo demonstrates superior 2-year and 3-year OS benefit compared with doc, and this benefit is observed across histology and PD-L1 expression subgroups (including TC0 and IC0). Atezo is well tolerated, and responses are highly durable. These results are consistent with long-term OS results from OAK (Satouchi, WCLC 2017). Acknowledgement of contribution: M. Gandhi, W. Yu, C. Matheny, P. He, A. Sandler, M. Ballinger, Genentech, Inc., South San Francisco, CA, USA.
Clinical trial identification:
NCT01903993
Legal entity responsible for the study:
F. Hoffmann-La Roche Ltd/Genentech, Inc.
Funding:
F. Hoffmann-La Roche Ltd/Genentech, Inc.
Disclosure:
K. Park: Consulting/Advisory Role: Astellas Pharma, AstraZeneca, Boehringer Ingelheim, Clovis Oncology, Lilly, Hanmi, Kyowa Hakko Kirin, Novartis, Ono Pharmaceutical, Roche. Speakers Bureau: Boehringer Ingelheim, Research Funding: AstraZeneca. C. Lewanski: Consultant: MSD, Roche, AstraZeneca. S. Gadgeel: Speaker's bureau- Astra-Zeneca, Genentech/Roche Advisory Boards: Astra-Zeneca, Ariad, Pfizer, Bristol Myers Squibb and Genentech/Roche. A. Rittmeyer: Grants as an advisor or speaker by: Astra Zeneca, BMS, Boehringer Ingelheim, Eli Lilly, Pfizer and Roche Genentech. A. Artal-Cortes: Advisory boards: Roche, BMS, MSD Travel fees: Roche. F. Braiteh: Speaking and consulting fees received From Genentech. M. Gandhi: Genentech employee and Roche stock. W. Yu: Genentech employee and Roche stock. C. Matheny: Genentech employee and Roche stock, Roche/Genentech travel, accommodations, expenses patents, royalties or other intellectual property: Stanford University (patient with Stanford, do not currently receive royalties or have other intellectual property). P. He: Genentech employee and Roche stock. A. Sandler: Genentech employee; Roche and Amgen stock, Husband has stocks for Allergan and Gilead. M. Ballinger: Genentech employee and Roche stock. All other authors have declared no conflicts of interest.
-
+
Uncommon driver alterations: Should we use off-label targeted agents? (ID 10)
- Event: ELCC 2018
- Type: Controversy session
- Track:
- Presentations: 1
- Now Available
- Moderators:E. Smit, F. Cappuzzo
- Coordinates: 4/12/2018, 09:15 - 10:15, Room A
-
+
Give an off-label prescription based on the best knowledge (Now Available) (ID 41)
09:45 - 10:05 | Presenting Author(s): J. Mazieres
- Abstract
- Presentation
Abstract not provided
Only Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login, select "Add to Cart" and proceed to checkout. If you would like to become a member of IASLC, please click here.
